Insomnia Insomnia

Psychophysiological Insomnia 79
43. Smith, S. and Trinder, J. (2001) Detecting insomnia: comparison of four self-report measures of
sleep in a young adult population. J. Sleep Res. 10(3), 229–235.
44. Leger, D., Scheuermaier, K., Philip, P., Paillard, M., and Guilleminault, C. (2001) SF-36: evaluation
of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom.
Med. 63(1), 49–55.
45. Roehrs, T., Papineau, K., Rosenthal, L., and Roth, T. (1999) Ethanol as a hypnotic in insomniacs:
self administration and effects on sleep and mood. Neuropsychopharmacology 20(3), 279–286.
46. Chang, P. P., Ford, D. E., Mead, L. A., Cooper-Patrick, L., and Klag, M. J. (1997) Insomnia in
young men and subsequent depression. The Johns Hopkins Precursors Study. Am. J. Epidemiol.
146(2), 105–114.
47. Roehrs, T. and Roth, T. (2000) Sleep-wake state and memory function. Sleep 23(Suppl 3), S64–S68.
48. Szelenberger, W. and Niemcewicz, S. (2000) Severity of insomnia correlates with cognitive impairment.
Acta Neurobiol. Exp. (Warsz) 60(3), 373.
49. Hajak, G. (2001) Epidemiology of severe insomnia and its consequences in Germany. Eur. Arch.
Psychiatry Clin. Neurosci. 251(2), 49–56.
50. Vgontzas, A. N. and Kales, A. (1999) Sleep and its disorders. Annu. Rev. Med. 50, 387–400.
51. Schenck, C. H. and Mahowald, M. W. (1996) Long-term, nightly benzodiazepine treatment of
injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am. J. Med.
100(3), 333–337.
52. Walsh, J. K. and Schweitzer, P. K. (1999) Ten-year trends in the pharmacological treatment of
insomnia. Sleep 22(3), 371–375.
53. Doghramji, K. (2000) The need for flexibility in dosing of hypnotic agents. Sleep 23(Suppl 1),
S16–S20; discussion S21–S2.
54. Darcourt, G., Pringuey, D., Salliere, D., and Lavoisy, J. (1999) The safety and tolerability of
zolpidem—an update. J. Psychopharmacol. 13(1), 81–93.
55. Holm, K. J. and Goa, K. L. (2000) Zolpidem: an update of its pharmacology, therapeutic efficacy
and tolerability in the treatment of insomnia. Drugs 59(4), 865–889.
56. Hajak, G. (1999) A comparative assessment of the risks and benefits of zopiclone: a review of 15
years’ clinical experience. Drug Saf. 21(6), 457–469.
57. Elie, R., Ruther, E., Farr, I., Emilien, G., and Salenas, E. (1999) Sleep latency is shortened during
4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study
Group. J. Clin. Psychiatry 60(8), 536–544.
58. Hedner, J., Yaeche, R., Emilieu, G., Farr, I., and Salinas, E. (2000) Zaleplon shortens subjective
sleep latency and improves subjective sleep quality in elderly patients with insomnia. The
Zaleplon Clinical Investigator Study Group. Int. J. Geriatr. Psychiatry 15(8), 704–712.
59. Dominguez, R. A., Bravo-Valverde, R. L., Kaplavitz, B. R., and Cott, J. M. (2000)Valerian as a
hypnotic for Hispanic patients. Cultur. Divers. Ethni. Minor Psychol. 6(1), 84–92.
60. Dorn, M. (2000) [Efficacy and tolerability of Baldrian versus oxazepam in non-organic and nonpsychiatric
insomniacs: a randomised, double-blind, clinical, comparative study]. Forsch.
Komplementarmed. Klass. Naturheilkd. 7(2), 79–84.
61. Weiler, J. M., Bloomfield, J. R., Woodworth, G. G., et al. (2000) Effects of fexofenadine, diphenhydramine,
and alcohol on driving performance. A randomized, placebo-controlled trial in the
Iowa driving simulator. Ann. Intern. Med. 132(5), 354–363.
62. Hajak, G., Cluydts, R., Declerck, A., et al. (2002) Continuous versus non-nightly use of zolpidem
in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int.
Clin. Psychopharmacol. 17(1), 9–17.
63. Beullens, J. (1999) [Determinants of insomnia in relatively healthy elderly. A literature review].
Tijdschr. Gerontol. Geriatr. 30(1), 31–38.
64. Morin, C. M., Mimeault, V., and Gagne, A. (1999) Nonpharmacological treatment of late-life
insomnia. J. Psychosom. Res. 46(2), 103–116.